Quarterly ResultMay 22, 2026, 04:18 PM
Abivax Obefazimod Study 108 Shows Durable UC Remission; Q1 Cash €491.6M
AI Summary
Abivax reported its Q1 2026 financial results and positive three-year interim data from Study 108, a Phase 2a/2b open-label extension trial of obefazimod in ulcerative colitis (UC). The study showed durable clinical remission in 68% of patients at week 144 following dose de-escalation, with no new safety signals observed over up to seven years of treatment. The company maintained a strong cash position of €491.6 million as of March 31, 2026, providing a cash runway into Q4 2027. Abivax anticipates topline results from its ABTECT Phase 3 maintenance trial in late Q2 2026 and plans for an NDA submission for obefazimod in UC in Q4 2026.
Key Highlights
- Study 108 interim analysis showed 68% (88/130) of UC patients in clinical remission at week 144 after dose de-escalation.
- 80% (104/130) of patients completed 144 weeks of treatment in Study 108, with no new safety signals observed.
- Cash, cash equivalents, and short-term investments were €491.6 million as of March 31, 2026.
- Projected cash runway extends into Q4 2027 based on current operating assumptions.
- R&D expenses increased by €10.2 million to €49.5 million in Q1 2026, primarily for new indications.
- G&A expenses decreased by €(1.7) million to €6.3 million in Q1 2026 due to lower personnel costs.
- Sales and marketing expenses increased by €0.9 million to €1.7 million in Q1 2026 for U.S. commercialization prep.
- Topline results for the ABTECT Phase 3 maintenance trial are expected in late Q2 2026.
- NDA submission for obefazimod in UC is targeted for Q4 2026, subject to positive data.
Price Impact
More from ABVX